Results 191 to 200 of about 49,566 (218)

High risk of clinical events in untreated HBeAg‐negative chronic hepatitis B patients with high viral load and no significant ALT elevation

Alimentary Pharmacology and Therapeutics, 2019
It remains unknown whether antiviral treatment for HBeAg‐negative chronic hepatitis B (CHB) patients having high viral loads without significant elevation of alanine aminotransferase (ALT) levels would reduce the risks of clinical events.
G. Choi, Gi-Ae Kim, Jonggi Choi, Seungbong Han, Y. Lim   +4 more
semanticscholar   +1 more source

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Hakan SentÜrk, Yilmaz Cakaloglu   +2 more
exaly   +2 more sources

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

New England Journal of Medicine, 2004
Patrick Marcellin, George Lau, Ferruccio Bonino   +2 more
exaly   +2 more sources

Relationship between hepatitis B core‐related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues

Journal of Viral Hepatitis, 2019
Hepatitis B e antigen (HBeAg) seroconversion experienced during nucleo(s)tide analogue (NUC) therapy is often not sustained. We aimed to study whether hepatitis B core‐related antigen (HBcrAg) levels predict sustained HBeAg seroconversion in patients ...
M. Sonneveld, G. V. van Oord, M. J. V. van Campenhout, R. D. de Man, H. Janssen, R. D. de Knegt, A. Boonstra, A. A. van der Eijk   +7 more
semanticscholar   +1 more source

Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy

Hepatology, 2017
Yan-Dan Ren, Zhen-shi Ye, Liu‐Zhu Yang, Li-Xin Jin, Wen-Jun Wei, Yong Deng, Xiao-xiao Chen, C. xiao, Xiao-Fang Yu, Hong‐zhi Xu, Lizhe Xu, Yunna Tang, Fei Zhou, Xue-Lian Wang, Mei-ya Chen, Ligang Chen, Mei-Zhu Hong, Jian‐lin Ren, Jin-Shui Pan   +18 more
semanticscholar   +1 more source

DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B

Antiviral Therapy, 2018
G. Papatheodoridis, E. Rigopoulou, M. Papatheodoridi, K. Zachou, V. Xourafas, N. Gatselis, E. Hadziyannis, J. Vlachogiannakos, S. Manolakopoulos, G. Dalekos   +9 more
semanticscholar   +1 more source

Ultrasensitive electrochemical immunosensor for quantitative detection of HBeAg using Au@Pd/MoS2@MWCNTs nanocomposite as enzyme-mimetic labels.

Biosensors & bioelectronics, 2018
Zengqiang Gao, Yueyun Li, Xiaobo Zhang, Jinhui Feng, Ling Kong, Ping Wang, Zhiwei Chen, Yun-hui Dong, Qin Wei   +8 more
semanticscholar   +1 more source

No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment

Journal of Viral Hepatitis, 2017
Yang Liu, A. Corsa, M. Buti, A. Cathcart, John F Flaherty, M. Miller, K. Kitrinos, P. Marcellin, E. Gane   +8 more
semanticscholar   +1 more source

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg‐positive patients treated with nucleos(t)ide analogues

Journal of Viral Hepatitis, 2018
Bo Wang, I. Carey, M. Bruce, S. Montague, G. Dusheiko, G. Dusheiko, K. Agarwal   +6 more
semanticscholar   +1 more source

Serum HBV core‐related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients

Journal of Medical Virology, 2017
G. Song, Rui‐feng Yang, H. Rao, B. Feng, Hui Ma, Q. Jin, Lai Wei   +6 more
semanticscholar   +1 more source